Drug Profile
Fentanyl transdermal - Luye Pharma
Alternative Names: FentaveraLatest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Acino
- Developer Acino; Luye Pharma Group
- Class Amides; Benzene derivatives; General anaesthetics; Opioid analgesics; Piperidines; Small molecules
- Mechanism of Action Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Pain
Most Recent Events
- 01 Dec 2016 Luye Pharma acquired Acino's Transdermal Drug Delivery System business
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in European Union (Transdermal, Patch)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in USA (Transdermal, Patch)